Agilent Technologies announced on April 14 2026 a three‑year strategic collaboration with South Korean AI firm OmixAI to advance AI‑driven proteomics research. The partnership will combine Agilent’s Bravo Automated Liquid Handling Platform with OmixAI’s proprietary multimodal database and AI‑powered experimentation capabilities, creating automated sample‑preparation workflows for large‑scale biological data analysis.
The collaboration focuses on joint research in targeted protein degradation, biomarker discovery and emerging therapeutic modalities, aiming to accelerate the identification of circulating biomarkers that could improve therapeutic outcomes. By leveraging OmixAI’s Cancer Surfaceome Atlas and Agilent’s automation technology, the alliance seeks to speed the development of antibody‑drug conjugates and protein‑degradation therapeutics.
The partnership is part of Agilent’s broader AI strategy, which includes acquisitions such as Sigsense Technologies and investments in AI‑enabled analytics. It positions Agilent to expand its AI‑enabled proteomics portfolio in South Korea, a rapidly growing precision‑medicine market. Agilent Korea Country General Manager Kang Hyun Hoo said the collaboration strengthens Agilent’s differentiated portfolio and supports translational research, while OmixAI CTO Park Jong Bae highlighted the potential to accelerate ADC and TPD development.
Agilent reported Q1 2026 revenue of $1.80 billion, up 7.0% YoY, but missed EPS estimates with $1.36 versus $1.37 expected. In Q4 2025, revenue was $1.86 billion, up 9.4% YoY, with EPS of $1.59 versus $1.58 expected. Full‑year 2025 revenue totaled $6.95 billion, and the company guided FY26 revenue to $7.3‑$7.5 billion with non‑GAAP EPS of $5.90‑$6.04. The partnership is expected to reinforce Agilent’s growth trajectory in high‑margin AI‑driven solutions.
The collaboration underscores Agilent’s commitment to embedding AI across its product and service lines, reinforcing its competitive edge in life‑sciences analytics. By establishing scalable, high‑throughput standards for protein profiling across South Korea’s research and biopharmaceutical ecosystems, Agilent aims to capture a larger share of the precision‑medicine market and accelerate the development of next‑generation therapeutics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.